Ramsay Stattman Vela & Price Inc. Sells 1,436 Shares of Danaher Co. (NYSE:DHR)

Ramsay Stattman Vela & Price Inc. reduced its position in shares of Danaher Co. (NYSE:DHR) by 2.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 68,552 shares of the conglomerate’s stock after selling 1,436 shares during the period. Danaher accounts for about 3.5% of Ramsay Stattman Vela & Price Inc.’s investment portfolio, making the stock its 6th largest position. Ramsay Stattman Vela & Price Inc.’s holdings in Danaher were worth $19,059,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. nVerses Capital LLC purchased a new position in shares of Danaher during the 2nd quarter worth about $25,000. CarsonAllaria Wealth Management Ltd. purchased a new position in Danaher in the second quarter valued at approximately $25,000. Redmont Wealth Advisors LLC purchased a new position in Danaher in the first quarter valued at approximately $30,000. MFA Wealth Advisors LLC purchased a new position in Danaher in the second quarter valued at approximately $51,000. Finally, Financial Connections Group Inc. purchased a new position in Danaher in the second quarter valued at approximately $51,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Danaher stock traded down $1.38 during midday trading on Tuesday, hitting $242.74. The company’s stock had a trading volume of 1,232,854 shares, compared to its average volume of 2,732,435. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The stock’s 50-day moving average price is $268.98 and its 200-day moving average price is $260.53. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a market capitalization of $179.79 billion, a PE ratio of 41.38, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the business posted $2.02 EPS. Analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Barclays cut their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Stifel Nicolaus lifted their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird dropped their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Raymond James decreased their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Stephens reissued an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $287.28.

Insider Activity at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,059 shares of company stock valued at $8,400,897. 11.10% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.